Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Black Diamond Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Black Diamond Therapeutics, Inc.

BDTX

Black Diamond Therapeutics, Inc.

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies—oral, small molecule inhibitors targeting families of oncogenic mutations across genetically defined cancers. Its proprietary MAP drug discovery engine identifies and inhibits mutation-driven cancer proteins with selectivity and brain penetration. Key programs focus on EGFR-mutant non-small cell lung cancer and glioblastoma. The company aims to address resistance and expand targeted treatment options for patients with limited therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Black Diamond Therapeutics, Inc.

1
1
Black Diamond Therapeutics, Inc. Black Diamond Therapeutics Reports Significant Financial Decline in Q1 2026

Via official filing (AI summary) | 30 days ago | 0 comments

2
1
Black Diamond Therapeutics, Inc. Black Diamond Therapeutics Reports $22.4 Million Net Income and Advances Silevertinib Trials

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Black Diamond Therapeutics, Inc. Black Diamond Therapeutics Reports $37.5M Net Income and $70M Licensing Agreement in Latest 10-Q

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Black Diamond Therapeutics, Inc. Black Diamond Therapeutics Reports $45.98 Million Net Income and Advances Silevertinib in Latest 10-Q

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Black Diamond Therapeutics, Inc. Black Diamond Therapeutics Reports $56.5 Million Net Income in Q1 2025, Driven by License Revenue

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Black Diamond Therapeutics, Inc. Black Diamond Therapeutics Reports $69.7 Million Net Loss for 2024, Highlights Progress in BDTX-1535 Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Black Diamond Therapeutics, Inc. Black Diamond Therapeutics Reports Improved Financials, Announces Corporate Restructuring Plan

Via official filing (AI summary) | over 1 year ago | 0 comments